Pharmaceutical Technology

APRIL 4, 2023

Indian pharma manufacturing continues to be the backbone of drug supplies worldwide, and GlobalData analysis suggests US overreliance on the country for generic drug supply. US reliance on India for generic drugs could have supply chain security and quality implications for critical medicines.

Manufacturing 130

Manufacturing Generic Drugs Contract Manufacturing Production 130

World of DTC Marketing

JANUARY 31, 2021

So where to start… Congresswoman Porter may want to look at the percentage of generic drugs available virus branded (89%). Ex vivo (where cells are genetically modified outside the body) cell and gene therapies have generated considerable excitement on their potential to cure previously incurable diseases.

In-Vivo 187

In-Vivo Generic Drugs Drugs Gene Therapy 187

pharmaphorum

FEBRUARY 2, 2022

Pharming has since started exploring new uses for the drug in acute kidney injury and COVID-19 pneumonia, whilst working on a gene therapy approach for HAE with Orchard Therapeutics. As it stands, the only other candidate for the disease listed in the clinicatrials.gov database is generic drug rapamycin.

Trials 52

Trials Drugs Sales Generic Drugs 52

XTalks

AUGUST 2, 2023

But all three drugs have new competitors. Meanwhile, BioMarin’s gene therapy Roctavian is approved by the FDA for the treatment of hemophilia A. Additionally, Bayer has formed a partnership with Mammoth Biosciences to broaden its product portfolio with innovative gene-editing technology. Both are anti-CD20 agents.

Sales 98

Sales Manufacturing FDA Approval Life Science 98

The Pharma Data

MAY 6, 2021

CSL closes deal for UniQure gene therapy in hopeful sign for M&A ( BioPharmaDive ). Dyno raises $100 million to bring artificial intelligence to gene therapy ( STAT ). Biogen’s Alzheimer’s drug may only be cost effective at $2,500 a year ( STAT ). OcuWho? .

Sales 52

Sales Vaccine Vaccination Gene Therapy 52

STAT News

FEBRUARY 14, 2023

WASHINGTON — The Biden administration on Tuesday announced three new drug pricing policy experiments that would standardize how much Medicare patients pay for certain generic drugs, pilot new ways for Medicaid to pay for pricey cell and gene therapies, and test ways to pay for drugs approved without proven clinical benefit to patients.

Drugs 98

Drugs Generic Drugs Gene Therapy Gene 98